Clinical trials: Asthmatic Patients
Severe Asthma
Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients
This study aims to generate real-world data on the characteristics of patients receiving benralizumab to assess early PRO parameters as well as long-term treatment effects in the Gulf cooperative council (Kingdom of Saudi Arabia…
- Trial name
- iOUTRUN (NCT05603845)
- Where
- 24 sites in Colombia, Dominican Republic and 6 more
- Volunteers
- 291 people
- Sponsor
- AstraZeneca
Asthma, Chronic Obstructive Pulmonary Disease
Trial Comparing Effect of He/O2 to Medical Air on Pulmonary Function Disease
This clinical trial will include healthy volunteers, COPD patients and asthmatic patients who will breathe He/O2 78:22, He/O2 65:35 and medical air consecutively in a randomised order.
- Conditions
- Asthma, Chronic Obstructive Pulmonary Disease, Healthy
- Trial name
- NCT00801307
- Testing
- spirometer
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Air Liquide SA
Asthma
Study Of RV-39 In Patients Who Also Have Asthma
This study will last up to 9 weeks. Subjects will visit the clinic up to 14 times. Certain clinic visits will include a physical examination, lung function tests, inflammatory cell analysis from nasal secretions and/or sputum…
- Trial name
- NCT00503009
- Testing
- fluticasone propionate/salmeterol, fluticasone propionate
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Rhinitis, Allergic, Seasonal, Asthma
Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 671800 ED using three dose levels of BI 671800 ED (50 mg, 200 mg and 400 mg), administered twice daily compared to FP (fluticasone…
- Trial name
- NCT01007721
- Testing
- BI 67100 ED 25 mg, BI 671800 ED 100 mg
- Where
- Germany
- Volunteers
- 146 people
- Sponsor
- Boehringer Ingelheim
Asthma
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
Primary Objective: To evaluate the efficacy of dupilumab in patients with persistent asthma Secondary Objectives: To evaluate the safety and tolerability of dupilumab To evaluate the effect of dupilumab on improving patient…
- Trial name
- NCT03782532
- Testing
- Dupilumab SAR231893, Asthma Controller Therapies (include prednisone/prednisolone), Asthma Reliever Therapies
- Where
- 67 sites in China, India
- Volunteers
- 486 people
- Sponsor
- Sanofi
Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients with Asthma
- Trial name
- eMOFEE (NCT04869384)
- Testing
- Reminders and feedback to improve adherence, No reminders and feedback to improve adherence
- Where
- Germany
- Volunteers
- 158 people
- Sponsor
- Orion Corporation, Orion Pharma
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- MM09-SIT-063 (NCT07904052)
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Asthma
Dose Finding Study for QAW039 in Asthma
This study aims to demonstrate a clinically significant improvement in Forced Expiratory Volume in one second (FEV1) in moderate to severe allergic asthmatics inadequately controlled by Inhaled Corticosteroid (ICS) therapy.
- Trial name
- NCT01437735
- Testing
- QAW039, Montelukast
- Where
- 206 sites in United States, Argentina and 20 more
- Volunteers
- 1,043 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Selective β2-AR Antagonism in Asthma
The objectives are to assess the safety, tolerability and effect on the airways of TR4 in patients with mild-to-moderate asthma. The Phase 1 trial is randomised, double-blind, placebo-controlled, and ascending-dose in design.
- Trial name
- NCT07272135
- Testing
- TR4
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Trio Medicines Ltd.
Asthma,, Chronic Obstructive Pulmonary Disease
Observational Study to Evaluate the Correctness of the Use of Inhaler Device in Patients With Asthma or Chronic Obstruct
The correct use of inhalation devices is an inclusion criterion for all studies comparing inhaled treatments. In real life, however, patients may make many errors with their usual inhalation device, which may negate the benefits…
- Trial name
- NCT01426893
- Where
- 5 sites in Serbia
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Asthma
New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
- Trial name
- BAI (NCT01360021)
- Testing
- Symbicort, Budesonide
- Where
- 41 sites in United States, Bulgaria and 2 more
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Moderate/Severe Asthma
NIS-observe Treatment Efficacy in Maintaining Symptoms Control in Moderate/Severe Asthma With Symbicort SMART
The primary objective of this non-interventional study is to evaluate efficacy of Symbicort® SMART treatment in adult patients with moderate to severe asthma using ACQ scores during 6 months period
- Trial name
- NCT00785733
- Where
- 44 sites in Romania
- Volunteers
- 1,182 people
- Sponsor
- AstraZeneca
Nasal Polyps
Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps
This study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Trial name
- ANCHOR-1 (NCT05274750)
- Testing
- Depemokimab (GSK3511294)
- Where
- 105 sites in United States, Argentina and 9 more
- Volunteers
- 276 people
- Sponsor
- GlaxoSmithKline
Bronchial Asthma
Efficacy and Tolerability of Beclomethasone Plus Salbutamol in HFA pMDI Fixed Combination vs Beclomethasone Plus Salbutamol in CFC pMDI Fixed Combination in a 12-week Treatment Period of Adult Patients With Uncontrolled Asthma
The purpose of this trial is to verify if the test treatment BDP 250 mcg/salbutamol 100 mcg HFA pMDI fixed combination is non-inferior to BDP 250 mcg/salbutamol 100 mcg pMDI fixed combination given with the conventional CFC…
- Trial name
- NCT00528723
- Testing
- salbutamol 100 mcg, BDP/salbutamol HFA pMDI, BDP/salbutamol CFC pMDI
- Where
- 25 sites in Italy, Russia and 2 more
- Volunteers
- 180 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma, COPD
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
The purpose of this clinical trial is to demonstrate hyperpolarized xenon (HXe) as a medical imaging drug (agent) for Magnetic Resonance Imaging (MRI) of the human lung ventilation.
- Conditions
- Asthma, COPD, Healthy
- Trial name
- HXe-VENT (NCT01833390)
- Testing
- HXe MRI lung ventilation
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Xemed LLC
Asthma
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
The objective of this study is to evaluate fluticasone furoate/vilanterol compared with fluticasone furoate alone in subjects with asthma that is uncontrolled on low to mid dose inhaled corticosteroid (ICS) or low dose ICS/ long…
- Trial name
- NCT03363191
- Testing
- Fluticasone Furoate/Vilanterol, Fluticasone Furoate, Salbutamol/Albuterol
- Sponsor
- GlaxoSmithKline
Asthma
Safety and Efficacy of GW685698X an Inhaled Corticosteroid Once Daily and Twice Daily for the Treatment of Asthma
The purpose of this study is to compare once and twice daily GW685698 in asthma
- Trial name
- NCT00766090
- Testing
- GW685698X
- Where
- 16 sites in United States
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
Allergy to House Dust Mite, Allergic Asthma
Effects of Tregalizumab on Allergen-induced Airway Responses and Airway Inflammation in Asthmatic Patients
The study will be conducted as a randomized, double-blind, placebo-controlled, single-center study in adult patients with mild controlled allergic asthma and house dust mite allergy.
- Trial name
- Tregulaire (NCT04673591)
- Testing
- Tregalizumab
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- T-Balance Therapeutics GmbH
Eosinophilic Asthma Patients
A Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
The purpose of this study is to evaluation the long-term Safety, Pharmacodynamics and Efficacy of SHR-1703 in Eosinophilic Asthma Patients
- Trial name
- NCT06441812
- Testing
- SHR-1703 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd